Adrian Tenorio, OD
Optometrist · Las Cruces, NMNPI 1174632335
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,910 of the $3,168 with a category attached, or 60.3%. 19 manufacturers reported payments, led by Alcon at 42.8% of the total. Reporting peaked in 2022 at $1,414 and has fallen 80.5% since, to $276 in 2025. Among optometrist clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $47.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Aerie Pharmaceuticals, Inc.$222
- Biotissue Holdings Inc.$210
- Dompe US, Inc.$187
- Bausch & Lomb, A Division Of Bausch Health US, LLC$161
- AbbVie$152
- plus $880 from 13 others
What the payments were for
- Speaking & faculty fees$1,13736%
- Food & beverage$1,91060%
- Gifts$371%
- Entertainment$843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 16 | $1,356 |
| Aerie Pharmaceuticals, Inc. | 4 | $222 |
| Biotissue Holdings Inc. | 7 | $210 |
| Dompe US, Inc. | 2 | $187 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $161 |
| AbbVie(2 entities) | 7 | $152 |
| Notal Vision, Inc. | 2 | $137 |
| Glaukos Corporation | 2 | $135 |
| Rxsight Inc | 1 | $131 |
| Shire North American Group Inc | 2 | $125 |
| Optos, Inc. | 2 | $84 |
| ABB Con-cise Optical Group LLC | 1 | $61 |
| Sun Pharmaceutical Industries Inc. | 4 | $60 |
| Oyster Point Pharma, Inc. | 3 | $50 |
| Bausch & Lomb Americas Inc. | 2 | $30 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIR OPTIX$1,000
- Air Optix plus HydraGlyde$1,000
- Dailies Aqua Comfort Plus$1,000
- DAILIES TOTAL1$1,000
- Precision 1$1,000
- RXSIGHT CONTACT LENS$131
- RXSIGHT INJECTOR CARTRIDGE$131
- RXSIGHT INJECTOR HANDPIECE$131
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$131
- LIGHT ADJUSTABLE LENS (LAL)$131
- Rhopressa$122
- Rocklatan$122
- XIIDRA$122
- Oxervate$109
How this compares
$3,168 in reported general payments places this provider in the 90th percentile of 228 optometrist providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $693,896 |
| RestasisCyclosporine | 79 | $114,082 |
| XdemvyLotilaner | 49 | $94,586 |
| LumiganBimatoprost | 71 | $30,147 |
| Cyclosporine | 30 | $12,860 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $7,211 |
| RhopressaNetarsudil Mesylate | 13 | $5,625 |
| Latanoprost | 422 | $5,586 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $4,946 |
| Brimonidine Tartrate | 34 | $3,339 |
| Travoprost | 21 | $2,693 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 186 | $2,361 |
| Prednisolone Acetate | 44 | $1,457 |
| Timolol Maleate | 70 | $1,204 |
| Ketorolac Tromethamine | 33 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $187 | $693,89613 claims |
| AbbVieRestasis, Lumigan, Combigan | $152 | $151,440171 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $19 | $94,58649 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $222 | $5,62513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 228 optometrist providers in New Mexico.
Other optometrist in Las Cruces
- Angela MorganLas Cruces$3K
- Jennifer MurrayLas Cruces$2K
- Carla WendlerLas Cruces$2K
- Thomas KunzLas Cruces$1K
- Matthew NewboldLas Cruces$1K
- Elisabeth HottelLas Cruces$979
- Keith BarkerClovis$52K
- Elysia IsonShiprock$37K
- David BabingtonAlbuquerque$8K
- David ViseSanta Fe$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.